Catalog No.
Product Name
Application
Product Information
Citations
-
Apoptosis Inducer
cpm-1285 is an apoptosis inducer that functionally inhibits intracellular Bcl-2 and related death antagonists. It demonstrates a strong binding affinity to Bcl-2, with an IC50 value of 130 nM. In preclinical studies, cpm-1285 effectively reduces tumor burden in murine models, making it a valuable tool for research on cancer therapies and the mechanisms of programmed cell death. -
Apoptosis Inducer
MYRA-A is a potent apoptosis inducer that targets the Myc pathway. It functions by inhibiting Myc transactivation and interfering with the DNA-binding activity of Myc family proteins, leading to decreased cell viability. MYRA-A is valuable for research in cancer biology, particularly in studies related to Myc-driven malignancies and the mechanisms of apoptosis. -
NF-κB p65 Inhibitor, Apoptosis Inducer
N-Desmethyldauricine is an inhibitor of NF-κB p65 with significant apoptotic effects. It effectively reduces p65 protein expression, induces apoptosis, and arrests the cell cycle at the G0/G1 phase. Additionally, N-Desmethyldauricine attenuates intercellular adhesion and inhibits the growth of 3D spheroids derived from triple-negative breast cancer. This compound is useful for research involving triple-negative breast cancer dynamics and therapeutic strategies. -
Apoptosis Inducer
Antitumor agent-149 is an apoptosis inducer that functions by inhibiting HIF-1α-mediated transcription. This compound effectively promotes apoptosis in cancer cells, thereby contributing to the suppression of tumor growth. In preclinical studies, Antitumor agent-149 demonstrated significant efficacy in inhibiting tumor progression in the SW620 xenograft mouse model, making it a valuable tool for cancer research. -
Apoptosis Inducer
Ganoderic acid Mf is a triterpenoid that acts as an apoptosis inducer, specifically targeting cancer cells. It promotes cell cycle arrest in the G1 phase, demonstrating significant selectivity for tumor versus normal cells. This compound induces apoptosis through a mitochondria-mediated pathway, making it a valuable reagent for cancer research and therapeutic studies. -
Apoptosis Inducer
Sanguinarine (gluconate) is a benzophenanthridine alkaloid that functions as an apoptosis inducer. It promotes apoptosis through the generation of reactive oxygen species (ROS) and is linked to the activation of key signaling pathways, including JNK and NF-κB. This compound is utilized in research exploring mechanisms of apoptosis and oxidative stress responses in various cell types. -
Apoptosis Inducer
Alpha-tocopheryloxyacetic acid (alpha-TEA) acts as an apoptosis inducer, specifically targeting pathways involved in programmed cell death. This compound demonstrates significant biological activity in promoting apoptosis in cancer cells, making it a valuable tool for research into both solid tumors and hematological malignancies. Its mechanism and application in oncological studies provide insights into potential therapeutic strategies for cancer treatment. -
Apoptosis Inducer
Apoptosis Inducer 8 is a compound that acts as a galectin-1 (gal-1) mediated apoptosis inducer, specifically designed to target and initiate cell death in lung cancer cells. This reagent has demonstrated a significant reduction in gal-1 protein levels, contributing to its efficacy as an anti-cancer agent. Additionally, Apoptosis Inducer 8 serves as a positron emission tomography (PET) imaging agent, facilitating research applications in cancer diagnosis and therapy monitoring. -
Apoptosis Inducer
Apoptosis Inducer 25 is a potent apoptosis inducer that specifically targets cell proliferation. It effectively inhibits the growth of BGC-823 cells with an IC50 of 0.37 μM, leading to cell cycle arrest in the G2/M phase. This compound further promotes apoptosis and triggers mitochondrial dysfunction, making it a valuable tool in cancer research. Its favorable pharmacokinetic profile in rat models underscores its potential for further investigation in therapeutic applications. -
p53 Inhibitor
YL-1-9 is a potent inhibitor of p53 degradation mediated by MDM2, achieved through its strong binding to critical hydrophobic pockets within the MDM2 protein. This compound effectively induces cell cycle arrest and promotes apoptosis, particularly in breast cancer cells. YL-1-9 is valuable for research into p53-targeted therapies and the mechanisms of cancer cell proliferation and survival. -
Apoptosis Inducer
Apoptosis Inducer 41 targets the mitochondrial pathway to trigger apoptosis in cancer cells. It displays potent inhibitory effects on MCF-7 cells, with an IC50 of 6.2 μM, and effectively induces cell cycle arrest in the G2/M phase. Additionally, Apoptosis Inducer 41 increases reactive oxygen species (ROS) accumulation and causes depolarization of the mitochondrial membrane potential. This compound is suitable for research focused on breast cancer and the mechanisms of programmed cell death. -
Apoptosis Inducer
Apoptosis Inducer 36 is a potent apoptosis inducer targeting leukemia cells. It demonstrates significant anti-leukemic activity by reducing leukemia stem cells and promoting differentiation. This compound inhibits the proliferation of acute myeloid leukemia (AML) cells, causes cell cycle arrest at the G1 phase, and stimulates PANoptosis, encompassing apoptosis, pyroptosis, and necrosis. A prodrug form of Apoptosis Inducer 36 shows orally active antitumor efficacy in mouse models, making it a valuable tool for research in cancer therapeutics. -
Apoptosis Inducer
Apoptosis Inducer 7 (Compound 5I) primarily targets apoptotic pathways to promote cell death in cancer cells. It activates the cleavage of PARP and caspases, while down-regulating the anti-apoptotic protein c-Flip and up-regulating the pro-apoptotic protein Noxa. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research focused on apoptosis mechanisms and therapeutic strategies. -
GP130 D1 domain inhibitor
(R)-JAK2/STAT3-IN-1 is a selective inhibitor of the GP130 D1 domain, primarily targeting the JAK2/STAT3 signaling pathway. This compound demonstrates significant anti-tumor activity by inhibiting the phosphorylation of JAK2 and STAT3, thereby impairing tumor cell viability and migration while promoting apoptosis. With an affinity of 3.8 μM for GP130, (R)-JAK2/STAT3-IN-1 serves as a valuable tool for research into cancer biology and therapeutic interventions. -
Apoptosis Inducer
Mechercharmycin A is a potent apoptosis inducer derived from the marine bacterium Thermoactinomyces sp. YM3-251. This compound demonstrates significant cytotoxicity and has shown strong antitumor activity in various biological models. It is utilized in research applications focusing on cancer cell apoptosis and the exploration of novel therapeutic strategies for tumor treatment. -
Apoptosis Inducer
Camellianin A, a potent apoptosis inducer, primarily targets cancer cell proliferation. Derived from the leaves of A. nitida, it exhibits significant anticancer activity, particularly in human Hep G2 and MCF-7 cell lines. Additionally, Camellianin A demonstrates angiotensin-converting enzyme (ACE) inhibitory effects, making it relevant for research in cancer therapy and cardiovascular studies. -
Apoptosis Inducer
Apoptosis Inducer 40 is a potent apoptosis inducer that primarily targets programmed cell death mechanisms. It demonstrates significant cytotoxic activity against Jurkat and NB4 cells, with IC50 values of 4.5 μM and 3.6 μM, respectively. By promoting apoptosis and cell cycle arrest, Apoptosis Inducer 40 is valuable for cancer research, particularly in studies focused on acute myeloid leukemia (AML). -
Apoptosis Inducer
Bax BH3 peptide (55-74), wild type is a 20-amino acid peptide derived from the BH3 domain of Bax, a pro-apoptotic protein that promotes cell death through mitochondrial pathway activation. This peptide is effective in inducing apoptosis across various cell line models and serves as a valuable tool for studying apoptosis mechanisms and the role of BH3-only proteins in cellular processes. Researchers can utilize this peptide for investigations into cancer therapeutics and programmed cell death pathways. -
Apoptosis Inducer
Antitumor agent-92 is an Icaritin derivative that functions as an apoptosis inducer. It effectively induces cell cycle arrest at the G0/G1 phase, leading to programmed cell death. This compound has significant potential for research applications in hepatocellular carcinoma (HCC) studies, providing a valuable tool for investigations into novel cancer therapies. -
Apoptosis Inducer
Anticancer agent 153 functions as an apoptosis inducer through the generation of reactive oxygen species (ROS). This compound disrupts mitochondrial membrane potential (MMP), leading to the initiation of programmed cell death and effectively inhibiting cancer cell proliferation. Anticancer agent 153 is a valuable tool for research applications focused on understanding apoptosis mechanisms and evaluating potential therapeutic strategies against cancer. -
ASK Inhibitor
ASK1-IN-6 is a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC50 of 7 nM in biochemical assays and 25 nM in cellular assays. This compound demonstrates potent anti-inflammatory properties and penetrates the blood-brain barrier, making it a valuable tool for studying neurodegenerative diseases, including Alzheimer's disease. Its specificity and efficacy position ASK1-IN-6 as a potential candidate for therapeutic exploration in related research applications. -
RET/BRAF/S6K/Src Inhibitor
AD57 is an orally active multikinase inhibitor that targets RET, BRAF, S6K, and Src, effectively reducing mTOR activity. This compound demonstrates significant biological activity by interfering with critical signaling pathways involved in cancer proliferation and survival. AD57 is suitable for research applications focused on cancer biology and therapeutic development against malignancies driven by these kinases. -
RET/BRAF/S6K/Src Inhibitor
AD57 hydrochloride is a multikinase inhibitor that targets RET, BRAF, S6K, and Src pathways. This orally active compound demonstrates significant biological activity in modulating aberrant signaling pathways associated with various cancers. Research applications include studying the effects of combined inhibition on tumor growth and resistance mechanisms in cancer cell lines and animal models. -
p53 DNA-binding inhibitor
NSC194598 is a p53 DNA-binding inhibitor that effectively disrupts the interaction between p53 and DNA, exhibiting an IC50 value of 180 nM for in vitro studies and a range of 2-40 μM for in vivo applications. This compound has been shown to interfere with the transcriptional activation of the mutated RET gene in human medullary thyroid carcinoma TT cells. NSC194598 is utilized in research investigating acute toxicity effects on normal tissues due to radiation and chemotherapy. -
RET Inhibitor
RET-IN-4 is a potent and selective RET inhibitor that demonstrates oral bioavailability, with IC50 values of 1.29 nM, 1.97 nM, and 0.99 nM against wild-type RET, RET V804M, and RET M918T variants, respectively. This compound exhibits improved selectivity against kinases such as JAK2 (IC50 of 4.4 nM) and FLT3 (IC50 of 30.8 nM). RET-IN-4 is primarily utilized in cancer research, highlighting its potential for therapeutic applications in RET-driven malignancies. -
p53 Reactivator
Roslin 2 bromide, also known as Benzylhexamethylenetetramine bromide, is a reactivator of the p53 tumor suppressor protein. By binding to focal adhesion kinase (FAK), Roslin 2 bromide disrupts the interaction between FAK and p53, thereby enhancing p53 activity and exhibiting potential anticancer effects. This compound is suitable for research applications focused on cancer biology and the modulation of p53 signaling pathways. -
RET Inhibitor
RET-IN-14 is a highly selective RET inhibitor that demonstrates potent inhibition with IC50 values of less than 0.51 nM for wild-type RET and varying nanomolar activity against RET mutations (G810R and V804M) as well as BTK and its C481S mutant. Its exceptional efficacy positions RET-IN-14 as a valuable tool for investigating RET-driven tumors and exploring therapeutic strategies in cancer research. -
c-KIT/PDGFR/RET Inhibitor
KBP-7018 is a selective tyrosine kinase inhibitor targeting c-KIT, PDGFR, and RET. It demonstrates potent inhibition with IC50 values of 10 nM for c-KIT, 7.6 nM for PDGFR, and 25 nM for RET. This compound is valuable for investigating the molecular mechanisms and potential treatments related to idiopathic pulmonary fibrosis. -
c-KIT/PDGFR/RET Inhibitor
KBP-7018 hydrochloride is a selective inhibitor of tyrosine kinases, specifically targeting c-KIT, PDGFR, and RET. It exhibits significant inhibitory potency, with IC50 values of 10 nM, 7.6 nM, and 25 nM, respectively. This compound is utilized in research focused on idiopathic pulmonary fibrosis, facilitating investigations into pathways associated with this condition. -
Survivin Antagonist
Shepherdin (79-87) is a peptidomimetic antagonist targeting the interaction between Heat Shock Protein 90 (Hsp90) and Survivin. This fragment, representing amino acids 79 to 87 of the full Shepherdin sequence, demonstrates significant anticancer activity by disrupting the chaperone function of Hsp90, leading to the destabilization of Survivin. It is primarily utilized in cancer research to explore mechanisms of apoptosis and investigate therapeutic strategies targeting cell survival pathways. -
Hsp70 Binder, Apoptosis Inducer
EV206 is a selective binder to the N-terminal domain of Hsp70, functioning as an apoptosis inducer. It promotes the degradation of Hsp70 through the ubiquitin-proteasome pathway, leading to reduced protein stability and inhibition of cellular growth. EV206 effectively induces apoptotic cell death in non-small cell lung cancer cells, suppresses colony formation, and downregulates markers associated with cancer stem cells. Additionally, it demonstrates anti-tumor activity in H460 xenograft models. This compound serves as a valuable tool for research in non-small cell lung cancer. -
ASK1 Inhibitor
CS17919 is a potent and selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1), exhibiting an IC50 of 22.52 nM. This compound demonstrates significant anti-inflammatory and antifibrotic effects, making it a valuable tool for investigating metabolic-related kidney and liver diseases. Its oral bioavailability enhances its utility in preclinical studies aimed at understanding ASK1's role in disease mechanisms and potential therapeutic interventions. -
ASK1 Inhibitor
DDO3711 is a specific inhibitor of apoptosis signal-regulated kinase 1 (ASK1), exhibiting an IC50 of 164.1 nM while displaying minimal inhibition of ASK2 (IC50 > 20 μM). This compound functions by dephosphorylating phosphorylated ASK1 at threonine 838 through recruitment of the phosphatase PP5. DDO3711 demonstrates significant ASK1-dependent antiproliferative effects and shows promise in studies related to cancer by targeting abnormally phosphorylated oncoproteins. -
ASK1 Inhibitor
JT21-25 is a potent and selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1), exhibiting an IC50 of 5.1 nM. This compound plays a crucial role in inhibiting apoptotic signaling pathways, making it valuable for research focused on cellular stress responses and apoptosis. JT21-25 is utilized in studies investigating the modulation of ASK1 activity in various disease models, particularly those related to neurodegenerative disorders and cancer. -
PPT1 Inhibitor
Ezurpimtrostat (hydrochloride) is a potent and selective PPT1 inhibitor with multiple biological activities. It disrupts lysosomal function, modulates autophagy, and induces apoptosis, making it a valuable tool in cancer research and immunology. This compound has demonstrated efficacy in reducing inflammatory markers such as IFN-α and CRP, as well as in lowering viral loads of SARS-CoV-2. Ezurpimtrostat is suitable for investigating conditions such as systemic lupus erythematosus, hepatocellular carcinoma, fibrosis, and other related disorders. -
Mdm2 E3 Ligase Inhibitor
MEL24 is an inhibitor of the Mdm2 E3 ligase, which plays a critical role in regulating p53 protein levels. This compound significantly reduces cell survival and enhances sensitivity to DNA-damaging agents in a p53-dependent manner. MEL24 is primarily utilized in antitumor research, contributing to studies aimed at understanding and overcoming resistance in cancer therapies. -
MDM2 Ligand
(rel)-Nutlin carboxylic acid is an MDM2 ligand derived from Nutlin 3, targeting the MDM2 protein to inhibit its interaction with p53. This compound plays a crucial role in cancer research, particularly in the study of p53 pathway modulation and potential therapeutic interventions. It can also be utilized in the development of PROTACs when linked to other proteins, facilitating targeted protein degradation. -
MDM2 E3 Ligase Inhibitor
MEL23 is an MDM2 E3 ligase inhibitor that specifically targets the E3 ligase activity of the MDM2-MDMX complex. This compound effectively inhibits the ubiquitination of MDM2 and p53, leading to decreased viability in cells expressing wild-type p53. Additionally, MEL23 stabilizes MDM2 through a mechanism that does not involve p53 transcription, making it a valuable tool for research into cancer biology and therapeutic strategies targeting the p53 pathway. -
Apoptosis Inducer
Triphenylphosphinechlorogold (Chloro(triphenylphosphine)gold(I)) targets apoptosis induction and acts as a catalyst in various biochemical reactions. This gold complex demonstrates significant lipoxygenase (LOX) inhibitory activity, leading to cell cycle arrest and apoptosis in cancer cells. Additionally, it catalyzes the peroxidation of linoleic acid and shows antiproliferative effects against breast cancer cell lines, contributing to its application in cancer research. A weak interaction with DNA may be involved in its mechanism of action, further highlighting its potential in therapeutic exploration. -
Caspase-3 Activator
Ru(acac)3 (Tris(acetylacetonato)ruthenium(III)) acts as a caspase-3 activator and apoptosis inducer. This compound demonstrates growth inhibitory effects on various cell lines in vitro, primarily by inhibiting DNA/RNA synthesis and inducing a mild, reversible S-phase cell cycle arrest. Ru(acac)3 is utilized in research focused on ovarian cancer, osteosarcoma, cervical cancer, melanoma, and other oncological studies. -
Apoptosis Inducer
Lumichrome is a photodegradation product of riboflavin that acts as an apoptosis inducer. It has been shown to inhibit the growth of human lung cancer cells and induce apoptosis through a p53-dependent mechanism. Additionally, Lumichrome serves as an inhibitor of the AKT/β-catenin signaling pathway, highlighting its potential utility in cancer research and therapeutic studies. -
Apoptosis Inducer
Karanjin is a furanoflavonoid with a primary mechanism as an apoptosis inducer. It demonstrates significant anti-cancer, anti-inflammatory, anti-diabetic, and antioxidant activities, making it a valuable compound for various research applications. Additionally, Karanjin exhibits protective effects against ulcerative conditions and Alzheimer’s disease, as well as insect repellent and acaricidal properties. Its diverse biological activities make it a promising candidate for studies in cancer therapy, inflammation, and neuroprotection. -
SLC7A11 Inhibitor, GPX4 Inhibitor
Anti-NSCLC agent-2 (compound 6o) functions as a dual inhibitor of SLC7A11 and GPX4, key regulators of ferroptosis. By disrupting redox homeostasis and depleting glutathione levels, this compound facilitates the accumulation of lipid peroxides, leading to the induction of ferroptosis in non-small cell lung cancer (NSCLC) cells. Anti-NSCLC agent-2 is a valuable tool for research focused on understanding and targeting non-small cell lung cancer mechanisms. -
Apoptosis Inducer
4′-O-Methylglabridin is an apoptosis inducer that disrupts the cell cycle and exhibits antioxidant and cytotoxic activities against cancer cells. It has been shown to inhibit a range of cancer cell lines, including liver, breast, and colorectal cancers, by reducing phosphorylated Rb and p21 protein levels, leading to an accumulation of cells in the subG1 and G2/M phases. Furthermore, 4′-O-Methylglabridin triggers caspase-dependent apoptosis through the release of cytochrome C and activation of caspase-9. Its antioxidant properties also include the inhibition of lipid peroxidation and prevention of LDL oxidation. This compound is valuable for research in cancer biology and atherosclerosis. -
Sphingolipid
C2 L-Erythro ceramide (d18:1/2:0) is a cell-permeable sphingolipid that primarily targets cellular sphingolipid pathways. It is known to induce cell cycle arrest in the G0/G1 phase, effectively inhibiting cell growth. This compound serves as a valuable tool for studying sphingolipid metabolism and its implications in cell cycle regulation and cancer research.
